Exploring the Physiologic, Pharmacodynamic, and Clinical Responses of Skeletal Muscle in Patients With Spinal Muscular Atrophy Treated With SMN-Directed Therapies

Study Identifier:

ML43225

ClinicalTrials.gov Identifier:

NCT06532474

EudraCT Identifier:

N/A

EU CT Number:

N/A

Recruiting

Study Details

Medical Condition

All Spinal Muscular Atrophies

Study Drug

Date

Oct 2025 - Sep 2026

Patient Requirements

Sex: Female & Male

Age: 5 - 20 Years

Requirements Information

Inclusion and Exclusion Criteria

Inclusion Criteria

Genetic confirmation of SMA with homozygous deletion of SMN1 or compound heterozygous deletion/mutation of SMN1
Two, three, or four copies of SMN2
Age 5 to 20 years
Non-ambulatory participants: maximum function sitting or standing with support, never walked independently, still able to sit independently for 5 seconds at screening, with active ankle plantar flexion strength of at least 3 N with hand-held myometry and capable of performing repetitive maximal plantar flexion effort for 120 seconds. HFMSE score at screening between 10 and 45 points.
Ambulatory participants: minimum function of independent walking, able to walk unassisted a minimum of 100 meters at screening, ankle plantar flexion strength of at least 10 N with hand-held myometry and capable of performing repetitive maximal plantar flexion for 120 seconds. HFMSE score at screening between 40 and 60.
SMN-directed therapy inclusion:
Current Evrysdi prescription
Must have Evrysdi prescription through their treating physician but have not yet initiated treatment OR
Current Spinraza or Zolgensma prescription
For patients on Spinraza, must have been taking Spinraza for at least 12 months at screening (4 loading and 2 maintenance doses) and following the FDA-recommended dosing schedule
For patients on Zolgensma, must have been dosed at least one year prior to screening
Must have Spinraza or Zolgensma prescription through their treating physician OR
Changing from Spinraza or Zolgensma to Evrysdi
For patients on Spinraza, must have been taking Spinraza for at least 12 months at screening (4 loading and 2 maintenance doses) and following the FDA-recommended dosing schedule
For patients on Zolgensma, must have been dosed at least one year prior to screening
Must have voluntarily decided to switch therapies based on discussion with their treating physician
Must have Evrysdi prescription through their treating physician but have not yet initiated treatment OR
Have never received any SMN-directed therapies

Exclusion Criteria

Labs at screening that are abnormal and identified as clinically significant by the PI: CBC, and CMP, liver function tests (over twice the upper limit of normal), PT/PTT, urine protein of 2+ or greater.
Inability to perform reliably the motor function testing or the exercise testing in the MR scanner.
Treatment with a possible SMA-enhancing or mitochondrial-enhancing medication, unless discontinued within 3 months prior to screening: oral albuterol, hydroxyurea, phenylbutryate, valproic acid, creatine, l-carnitine, or other mitochondrial type supplement (riboflavin, lipoic acid, etc.). A daily multivitamin and Vitamin D supplement and intermittent inhaled albuterol are permitted if the dosage is unchanged during the study.
Need for routine non-invasive ventilation support.
Non-oral nutritional support, e.g., gastrostomy tube feeding.
Any ferrous metal implants (e.g., spinal rods) that preclude testing in a MR scanner.

Protocol Summary

In this observational study, researchers are looking at the effects of spinal muscular atrophy (SMA) drugs on the muscles and nerve cells in patients with SMA.

Primary Objectives

To evaluate the feasibility and reliability of performing MR functional imaging in exercising muscle in patients with SMA.
To evaluate patients with SMA types 2 and 3 at baseline and longitudinally at 6 and 12 months

Secondary Objectives

To describe the MR functional bioenergetics response in the leg muscles in four potential groups of patients with spinal muscular atrophy: untreated, actively treated with nusinersen (Spinraza®) or onasemnogene abeparvovec (Zolgensma®), actively treated with risdiplam (Evrysdi®), and switching from Spinraza or Zolgensma to Evrysdi.
To identify changes in motor function in patients with SMA types 2 and 3 who initiate treatment with risdiplam.
To obtain biomarkers in blood, urine, and muscle tissue to provide proof-of-concept support for risdiplam effect on skeletal muscle.
To obtain quality of life and disability data from participants in this study.

Trial Locations

Location

Status

Location

St. Jude Children's Research Hospital

Memphis, Tennessee, United States, 38105

Status

Recruiting

Contact Cure SMA

User Information

If you have general questions regarding clinical trials or would like to be added to the Cure SMA mailing list to receive communications regarding future registries, studies, or clinical trials in SMA, please fill out the form below. Fields marked with an asterisk (*) are mandatory.

Requestors Information

Disability Advocate who does not have SMA
I am a healthcare provider
I am a researcher
I have no direct connection to SMA
I have SMA
I lost a child to SMA
My child has SMA
Someone close to me has/had SMA

Full Name

Phone Number

Country

Australia
Belgium
Brazil
Canada
Chile
China
Colombia
Croatia
Czech Republic
Denmark
Estonia
France
Germany
Greece
Hong Kong
Hungary
India
Ireland
Israel
Italy
Japan
Lebanon
Malaysia
Mexico
Netherlands
Norway
Poland
Portugal
Puerto Rico
Qatar
Republic of Korea
Romania
Russian Federation
Saudi Arabia
Serbia
Singapore
South Africa
Spain
Sweden
Switzerland
Taiwan, Province of China
Thailand
Ukraine
United Kingdom
United States
Vietnam

State

City

Postal Code

Message

I have read and agree to the Release Consent

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.